CFO David Parrot purchases 2,666 shares at $15.00 in SCTX private placement allocation during recent IPO
David Parrot, Chief Financial Officer of Scribe Therapeutics, acquired 2,666 shares through 2 separate purchases at $15.00 on 2026-07-23, investing $39,990.00 total. This transaction is flagged as a private placement allocation, not a discretionary open-market purchase, and therefore does not reflect insider conviction about the stock's direction. Scribe is a recent IPO listing (2 trading days old as of the price reference date), making traditional valuation and conviction-based interpretation inappropriate. Parrot maintains substantial derivative holdings totaling 227,761 shares across three option grants (8,909 and 109,426 shares each across two standard options, plus 109,426 performance-based shares), indicating meaningful longer-term equity alignment with the company's success.